ophthalmology

News

Roche builds gene therapy portfolio with SpliceBio deal

Roche’s gene therapy unit Spark has added to its pipeline in inherited retinal diseases (IRDs) with a $216 million alliance with Spanish biotech SpliceBio.

News

Novartis drops geographic atrophy gene therapy

Novartis has confirmed it will discontinue development of a gene therapy for sight-robbing disease geographic atrophy (GA) two years after acquiring its UK-based developer

News

Outlook slumps as FDA rejects eye disease drug

Shares in Outlook Therapeutics cratered today after the FDA rejected the company's marketing application for its lead drug ONS-5010, a therapy for age-related macular dege

News

After earlier rejection, high-dose Eylea clears FDA

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the

R&D